HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Market Overview:
The global HIV drugs market size reached US$ 30.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 38.8 Billion by 2028, exhibiting a growth rate (CAGR) of 3.95% during 2023-2028.
Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV, thereby reducing the risk of its transmission.
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global HIV drugs market report, along with forecasts at the global and regional levels from 2023-2028. Our report has categorized the market based on drug class and distribution channel.
Breakup by Drug Class:
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global HIV drugs market report, along with forecasts at the global and regional levels from 2023-2028. Our report has categorized the market based on drug class and distribution channel.
Breakup by Drug Class:
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.
Competitive Landscape:
The competitive landscape of the market has also been examined with some of the key players being Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Gilead Sciences, Inc., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan.
This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.
Key Questions Answered in This Report
1. What was the size of the global HIV drugs market in 2022?
2. What is the expected growth rate of the global HIV drugs market during 2023-2028?
3. What has been the impact of COVID-19 on the global HIV drugs market?
4. What are the key factors driving the global HIV drugs market?
5. What is the breakup of the global HIV drugs market based on the drug class?
6. What is the breakup of the global HIV drugs market based on the distribution channel?
7. What are the key regions in the global HIV drugs market?
8. Who are the key players/companies in the global HIV drugs market?
The global HIV drugs market size reached US$ 30.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 38.8 Billion by 2028, exhibiting a growth rate (CAGR) of 3.95% during 2023-2028.
Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV, thereby reducing the risk of its transmission.
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global HIV drugs market report, along with forecasts at the global and regional levels from 2023-2028. Our report has categorized the market based on drug class and distribution channel.
Breakup by Drug Class:
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global HIV drugs market report, along with forecasts at the global and regional levels from 2023-2028. Our report has categorized the market based on drug class and distribution channel.
Breakup by Drug Class:
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.
Competitive Landscape:
The competitive landscape of the market has also been examined with some of the key players being Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Gilead Sciences, Inc., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan.
This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.
Key Questions Answered in This Report
1. What was the size of the global HIV drugs market in 2022?
2. What is the expected growth rate of the global HIV drugs market during 2023-2028?
3. What has been the impact of COVID-19 on the global HIV drugs market?
4. What are the key factors driving the global HIV drugs market?
5. What is the breakup of the global HIV drugs market based on the drug class?
6. What is the breakup of the global HIV drugs market based on the distribution channel?
7. What are the key regions in the global HIV drugs market?
8. Who are the key players/companies in the global HIV drugs market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1Objectives of the Study
2.2Stakeholders
2.3Data Sources
2.3.1Primary Sources
2.3.2Secondary Sources
2.4Market Estimation
2.4.1Bottom-Up Approach
2.4.2Top-Down Approach
2.5Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1Overview
4.2Key Industry Trends
5 GLOBAL HIV DRUGS MARKET
5.1Market Overview
5.2Market Performance
5.3Impact of COVID-19
5.4Price Analysis
5.5Market Breakup by Drug Class
5.6Market Breakup by Distribution Channel
5.7Market Breakup by Region
5.8Market Forecast
5.9SWOT Analysis
5.9.1 Overview
5.9.2 Strengths
5.9.3 Weaknesses
5.9.4 Opportunities
5.9.5 Threats
5.10Value Chain Analysis
5.10.1 Overview
5.10.2 Research and Development
5.10.3 Raw Material Procurement
5.10.4 Manufacturing
5.10.5 Marketing
5.10.6 Distribution
5.10.7 End-Use
5.11Porters Five Forces Analysis
5.11.1 Overview
5.11.2 Bargaining Power of Buyers
5.11.3 Bargaining Power of Suppliers
5.11.4 Degree of Competition
5.11.5 Threat of New Entrants
5.11.6 Threat of Substitutes
6 MARKET BREAKUP BY DRUG CLASS
6.1Nucleoside Reverse Transcriptase Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2Multi-Class Combination Products
6.2.1 Market Trends
6.2.2 Market Forecast
6.3Protease Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
6.4HIV Integrase Strand Transfer Inhibitors
6.4.1 Market Trends
6.4.2 Market Forecast
6.5Non-Nucleoside Reverse Transcriptase Inhibitors
6.5.1 Market Trends
6.5.2 Market Forecast
6.6Entry Inhibitors — CCR5 Co-Receptor Antagonist
6.6.1 Market Trends
6.6.2 Market Forecast
6.7Fusion Inhibitors and Others
6.7.1 Market Trends
6.7.2 Market Forecast
7 MARKET BREAKUP BY DISTRIBUTION CHANNEL
7.1Hospital Pharmacies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2Retail Pharmacies
7.2.1 Market Trends
7.2.2 Market Forecast
7.3Online Pharmacies
7.3.1 Market Trends
7.3.2 Market Forecast
7.4Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 MARKET BREAKUP BY REGION
8.1North America
8.1.1 Market Trends
8.1.2 Market Forecast
8.2Europe
8.2.1 Market Trends
8.2.2 Market Forecast
8.3Asia Pacific
8.3.1 Market Trends
8.3.2 Market Forecast
8.4Middle East and Africa
8.4.1 Market Trends
8.4.2 Market Forecast
8.5Latin America
8.5.1 Market Trends
8.5.2 Market Forecast
9 HIV DRUGS MANUFACTURING PROCESS
9.1Product Overview
9.2Raw Material Requirements
9.3Manufacturing Process
9.4Key Success and Risk Factors
10 COMPETITIVE LANDSCAPE
10.1Market Structure
10.2Market Breakup by Key Players
10.3Profiles of Key Players
10.3.1 Boehringer Ingelheim International GmbH
10.3.2 Merck & Co., Inc.
10.3.3 ViiV Healthcare
10.3.4 AbbVie
10.3.5 F. Hoffmann-La Roche Ltd.
10.3.6 Teva Pharmaceutical Industries Ltd.
10.3.7 Bristol-Myers Squibb
10.3.8 Gilead Sciences, Inc.
10.3.9 Johnson & Johnson
10.3.10 Cipla Limited
10.3.11 Daiichi Sankyo
10.3.12 Emcure
10.3.13 Hetero Drugs
10.3.14 Mylan
2 SCOPE AND METHODOLOGY
2.1Objectives of the Study
2.2Stakeholders
2.3Data Sources
2.3.1Primary Sources
2.3.2Secondary Sources
2.4Market Estimation
2.4.1Bottom-Up Approach
2.4.2Top-Down Approach
2.5Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1Overview
4.2Key Industry Trends
5 GLOBAL HIV DRUGS MARKET
5.1Market Overview
5.2Market Performance
5.3Impact of COVID-19
5.4Price Analysis
5.5Market Breakup by Drug Class
5.6Market Breakup by Distribution Channel
5.7Market Breakup by Region
5.8Market Forecast
5.9SWOT Analysis
5.9.1 Overview
5.9.2 Strengths
5.9.3 Weaknesses
5.9.4 Opportunities
5.9.5 Threats
5.10Value Chain Analysis
5.10.1 Overview
5.10.2 Research and Development
5.10.3 Raw Material Procurement
5.10.4 Manufacturing
5.10.5 Marketing
5.10.6 Distribution
5.10.7 End-Use
5.11Porters Five Forces Analysis
5.11.1 Overview
5.11.2 Bargaining Power of Buyers
5.11.3 Bargaining Power of Suppliers
5.11.4 Degree of Competition
5.11.5 Threat of New Entrants
5.11.6 Threat of Substitutes
6 MARKET BREAKUP BY DRUG CLASS
6.1Nucleoside Reverse Transcriptase Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2Multi-Class Combination Products
6.2.1 Market Trends
6.2.2 Market Forecast
6.3Protease Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
6.4HIV Integrase Strand Transfer Inhibitors
6.4.1 Market Trends
6.4.2 Market Forecast
6.5Non-Nucleoside Reverse Transcriptase Inhibitors
6.5.1 Market Trends
6.5.2 Market Forecast
6.6Entry Inhibitors — CCR5 Co-Receptor Antagonist
6.6.1 Market Trends
6.6.2 Market Forecast
6.7Fusion Inhibitors and Others
6.7.1 Market Trends
6.7.2 Market Forecast
7 MARKET BREAKUP BY DISTRIBUTION CHANNEL
7.1Hospital Pharmacies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2Retail Pharmacies
7.2.1 Market Trends
7.2.2 Market Forecast
7.3Online Pharmacies
7.3.1 Market Trends
7.3.2 Market Forecast
7.4Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 MARKET BREAKUP BY REGION
8.1North America
8.1.1 Market Trends
8.1.2 Market Forecast
8.2Europe
8.2.1 Market Trends
8.2.2 Market Forecast
8.3Asia Pacific
8.3.1 Market Trends
8.3.2 Market Forecast
8.4Middle East and Africa
8.4.1 Market Trends
8.4.2 Market Forecast
8.5Latin America
8.5.1 Market Trends
8.5.2 Market Forecast
9 HIV DRUGS MANUFACTURING PROCESS
9.1Product Overview
9.2Raw Material Requirements
9.3Manufacturing Process
9.4Key Success and Risk Factors
10 COMPETITIVE LANDSCAPE
10.1Market Structure
10.2Market Breakup by Key Players
10.3Profiles of Key Players
10.3.1 Boehringer Ingelheim International GmbH
10.3.2 Merck & Co., Inc.
10.3.3 ViiV Healthcare
10.3.4 AbbVie
10.3.5 F. Hoffmann-La Roche Ltd.
10.3.6 Teva Pharmaceutical Industries Ltd.
10.3.7 Bristol-Myers Squibb
10.3.8 Gilead Sciences, Inc.
10.3.9 Johnson & Johnson
10.3.10 Cipla Limited
10.3.11 Daiichi Sankyo
10.3.12 Emcure
10.3.13 Hetero Drugs
10.3.14 Mylan
LIST OF TABLES
Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 5: HIV Drugs Manufacturing: Raw Material Requirements
Table 6: Global: HIV Drugs Market: Competitive Structure
Table 7: Global: HIV Drugs Market: Key Players
Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 5: HIV Drugs Manufacturing: Raw Material Requirements
Table 6: Global: HIV Drugs Market: Competitive Structure
Table 7: Global: HIV Drugs Market: Key Players
LIST OF FIGURES
Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
Figure 2: Global: HIV Drugs Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2022
Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2022
Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2022
Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 7: Global: HIV Drugs Industry: SWOT Analysis
Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
Figure 9: Global: HIV Drugs Industry: Porter’s Five Forces Analysis
Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: HIV Drugs (Fusion Inhibitors and Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: HIV Drugs (Fusion Inhibitors and Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2017 & 2022
Figure 25: Global: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2023-2028
Figure 26: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million US$), 2017 & 2022
Figure 27: Global: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2023-2028
Figure 28: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million US$), 2017 & 2022
Figure 29: Global: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2023-2028
Figure 30: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million US$), 2017 & 2022
Figure 31: Global: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2023-2028
Figure 32: North America: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: North America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: Europe: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: Europe: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: Asia Pacific: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: Asia Pacific: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: Middle East and Africa: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: Middle East and Africa: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: Latin America: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: Latin America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: HIV Drugs Manufacturing: Detailed Process Flow
Figure 43: Global: HIV Drugs Market: Breakup by Key Players (in %)
Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
Figure 2: Global: HIV Drugs Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2022
Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2022
Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2022
Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 7: Global: HIV Drugs Industry: SWOT Analysis
Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
Figure 9: Global: HIV Drugs Industry: Porter’s Five Forces Analysis
Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: HIV Drugs (Fusion Inhibitors and Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: HIV Drugs (Fusion Inhibitors and Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2017 & 2022
Figure 25: Global: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2023-2028
Figure 26: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million US$), 2017 & 2022
Figure 27: Global: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2023-2028
Figure 28: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million US$), 2017 & 2022
Figure 29: Global: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2023-2028
Figure 30: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million US$), 2017 & 2022
Figure 31: Global: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2023-2028
Figure 32: North America: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: North America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: Europe: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: Europe: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: Asia Pacific: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: Asia Pacific: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: Middle East and Africa: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: Middle East and Africa: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: Latin America: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: Latin America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: HIV Drugs Manufacturing: Detailed Process Flow
Figure 43: Global: HIV Drugs Market: Breakup by Key Players (in %)
